OrbiMed Partners, Ltd.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$2.6B
Investors
779
Min Invest
$100,000
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
OrbiMed Partners, Ltd. is a Virgin Islands, British entity that first filed a Form D on March 12, 2012 and most recently amended it on July 10, 2026, describing itself as a hedge fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(7) and covers equity and pooled investment fund interests. OrbiMed Partners, Ltd. reported $2,611,956,097 sold from 779 investors in an offering of indefinite size as of the Form D filed July 10, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports non-accredited investors. The minimum investment accepted from an outside investor is $100,000. The Form D names Far Hills Group, LLC (CRD 000032243), associated with None as the recipient of sales compensation soliciting in all states. The issuer's address of record is 601 Lexington Avenue, 54th Floor, New York, NY 10022.
Critical Disclosures
What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.
Offering stalled · Form D · last filing July 10, 2026
Latest annual amendment reported no change in amount sold or investors
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
3
latest Jul 10, 2026
Critical / warning
0 / 0
3 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
stalled
Latest event Stalled · Jul 10, 2026
SEC.govFund family Part of the OrbiMed Partners family: 3 vehicles across 1 generation · full family and the filing behind each link in the terminal
Investor
- The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
- 3 filing events with values and deltas, latest 2026-07-10, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
OrbiMed Capital LLC
Promoter · NEW YORK, NY
Investment Advisor
Sven H. Borho
Director · NEW YORK, NY
Brian Burkholder
Director · George Town, Grand Cayman, E9
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Far Hills Group, LLCCRD 000032243 on BrokerCheck
Associated broker-dealer: None · NEW YORK, NY · Soliciting in all states
Questions About OrbiMed Partners, Ltd.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is OrbiMed Partners, Ltd.?
OrbiMed Partners, Ltd. is a Virgin Islands, British entity that filed a Form D with the SEC on July 10, 2026 as a hedge fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of equity and pooled investment fund interests.
Is OrbiMed Partners, Ltd. legit?
AltStreet does not rate legitimacy; it reports the public record. OrbiMed Partners, Ltd. filed a Form D with the SEC on July 10, 2026 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $2,611,956,097 sold to 779 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is OrbiMed Partners, Ltd. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that OrbiMed Partners, Ltd. claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has OrbiMed Partners, Ltd. raised?
OrbiMed Partners, Ltd. reported $2,611,956,097 sold from 779 investors in an offering of indefinite size as of the Form D filed July 10, 2026.
Who can invest in OrbiMed Partners, Ltd.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports non-accredited investors. The minimum investment accepted from an outside investor is $100,000.
What is the minimum investment in OrbiMed Partners, Ltd.?
The Form D lists $100,000 as the minimum investment accepted from any outside investor as of July 10, 2026. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling OrbiMed Partners, Ltd. and how are they paid?
The Form D names Far Hills Group, LLC (CRD 000032243), associated with None as the recipient of sales compensation soliciting in all states.
Who is behind OrbiMed Partners, Ltd.?
The Form D lists 3 related persons: OrbiMed Capital LLC, promoter (Investment Advisor); Sven H. Borho, director; Brian Burkholder, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is OrbiMed Partners, Ltd. located?
The issuer's address on its SEC filings is 601 Lexington Avenue, 54th Floor, New York, NY 10022. Its phone number of record is 212-739-6400. It is organized under the laws of Virgin Islands, British.
How long is the OrbiMed Partners, Ltd. offering open?
The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 14 amendments are on record for this CIK.
How large is OrbiMed Partners, Ltd.?
The issuer declined to disclose its net asset value range on the Form D, which the form permits.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
